Copyright Reports & Markets. All rights reserved.

Global Bio Similars/Subsequent Entry Biologic Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Bio Similars/Subsequent Entry Biologic Market Overview

    • 1.1 Product Overview and Scope of Bio Similars/Subsequent Entry Biologic
    • 1.2 Classification of Bio Similars/Subsequent Entry Biologic by Types
      • 1.2.1 Global Bio Similars/Subsequent Entry Biologic Revenue Comparison by Types (2019-2024)
      • 1.2.2 Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Types in 2018
      • 1.2.3 Monoclonal Antibodies
      • 1.2.4 Interferon
      • 1.2.5 Erythropoietin
      • 1.2.6 Insulin
      • 1.2.7 Vaccines
      • 1.2.8 Other
    • 1.3 Global Bio Similars/Subsequent Entry Biologic Market by Application
      • 1.3.1 Global Bio Similars/Subsequent Entry Biologic Market Size and Market Share Comparison by Applications (2014-2024)
      • 1.3.2 Tumor
      • 1.3.3 Diabetes
      • 1.3.4 Cardiovascular
      • 1.3.5 Hemophilia
      • 1.3.6 Other
    • 1.4 Global Bio Similars/Subsequent Entry Biologic Market by Regions
      • 1.4.1 Global Bio Similars/Subsequent Entry Biologic Market Size (Million USD) Comparison by Regions (2014-2024)
      • 1.4.1 North America (USA, Canada and Mexico) Bio Similars/Subsequent Entry Biologic Status and Prospect (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Bio Similars/Subsequent Entry Biologic Status and Prospect (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Bio Similars/Subsequent Entry Biologic Status and Prospect (2014-2024)
      • 1.4.4 South America (Brazil, Argentina, Colombia) Bio Similars/Subsequent Entry Biologic Status and Prospect (2014-2024)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Bio Similars/Subsequent Entry Biologic Status and Prospect (2014-2024)
    • 1.5 Global Market Size of Bio Similars/Subsequent Entry Biologic (2014-2024)

    2 Manufacturers Profiles

    • 2.1 Sun Pharma
      • 2.1.1 Business Overview
      • 2.1.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Sun Pharma Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Synthon Pharmaceuticals
      • 2.2.1 Business Overview
      • 2.2.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Synthon Pharmaceuticals Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Teva Pharmaceutical Industries
      • 2.3.1 Business Overview
      • 2.3.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Teva Pharmaceutical Industries Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 LG Life Sciences
      • 2.4.1 Business Overview
      • 2.4.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 LG Life Sciences Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Celltrion Biocon
      • 2.5.1 Business Overview
      • 2.5.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Celltrion Biocon Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Hospira
      • 2.6.1 Business Overview
      • 2.6.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Hospira Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Merck
      • 2.7.1 Business Overview
      • 2.7.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Merck Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Biogen idec
      • 2.8.1 Business Overview
      • 2.8.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Biogen idec Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Genentech (Roche)
      • 2.9.1 Business Overview
      • 2.9.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Genentech (Roche) Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 Pfizer
      • 2.10.1 Business Overview
      • 2.10.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Pfizer Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.11 Celltrion
      • 2.11.1 Business Overview
      • 2.11.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.11.2.1 Product A
        • 2.11.2.2 Product B
      • 2.11.3 Celltrion Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.12 Biocon
      • 2.12.1 Business Overview
      • 2.12.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.12.2.1 Product A
        • 2.12.2.2 Product B
      • 2.12.3 Biocon Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.13 Amgen
      • 2.13.1 Business Overview
      • 2.13.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.13.2.1 Product A
        • 2.13.2.2 Product B
      • 2.13.3 Amgen Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.14 Samsung Biologics
      • 2.14.1 Business Overview
      • 2.14.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.14.2.1 Product A
        • 2.14.2.2 Product B
      • 2.14.3 Samsung Biologics Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.15 Mylan
      • 2.15.1 Business Overview
      • 2.15.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.15.2.1 Product A
        • 2.15.2.2 Product B
      • 2.15.3 Mylan Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.16 Dr. Reddy's Laboratories
      • 2.16.1 Business Overview
      • 2.16.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.16.2.1 Product A
        • 2.16.2.2 Product B
      • 2.16.3 Dr. Reddy's Laboratories Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.17 Stada Arzneimittel AG
      • 2.17.1 Business Overview
      • 2.17.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.17.2.1 Product A
        • 2.17.2.2 Product B
      • 2.17.3 Stada Arzneimittel AG Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.18 AbbVie
      • 2.18.1 Business Overview
      • 2.18.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.18.2.1 Product A
        • 2.18.2.2 Product B
      • 2.18.3 AbbVie Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.19 Sanofi-Aventis
      • 2.19.1 Business Overview
      • 2.19.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.19.2.1 Product A
        • 2.19.2.2 Product B
      • 2.19.3 Sanofi-Aventis Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.20 Johnson & Johnson
      • 2.20.1 Business Overview
      • 2.20.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.20.2.1 Product A
        • 2.20.2.2 Product B
      • 2.20.3 Johnson & Johnson Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.21 Novo Nordisk
      • 2.21.1 Business Overview
      • 2.2.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.21.2.1 Product A
        • 2.21.2.2 Product B
      • 2.21.3 Novo Nordisk Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.22 Eli Lilly
      • 2.22.1 Business Overview
      • 2.22.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.22.2.1 Product A
        • 2.22.2.2 Product B
      • 2.22.3 Eli Lilly Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.23 Novartis
      • 2.23.1 Business Overview
      • 2.23.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.23.2.1 Product A
        • 2.23.2.2 Product B
      • 2.23.3 Novartis Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.24 3sbio
      • 2.24.1 Business Overview
      • 2.24.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.24.2.1 Product A
        • 2.24.2.2 Product B
      • 2.24.3 3sbio Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.25 Biotech
      • 2.25.1 Business Overview
      • 2.25.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.25.2.1 Product A
        • 2.25.2.2 Product B
      • 2.25.3 Biotech Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.26 Gelgen
      • 2.26.1 Business Overview
      • 2.26.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.26.2.1 Product A
        • 2.26.2.2 Product B
      • 2.26.3 Gelgen Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.27 Innovent
      • 2.27.1 Business Overview
      • 2.27.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.27.2.1 Product A
        • 2.27.2.2 Product B
      • 2.27.3 Innovent Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.28 Dong Bao
      • 2.28.1 Business Overview
      • 2.28.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.28.2.1 Product A
        • 2.28.2.2 Product B
      • 2.28.3 Dong Bao Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)
    • 2.29 Ganlee
      • 2.29.1 Business Overview
      • 2.29.2 Bio Similars/Subsequent Entry Biologic Type and Applications
        • 2.29.2.1 Product A
        • 2.29.2.2 Product B
      • 2.29.3 Ganlee Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Bio Similars/Subsequent Entry Biologic Market Competition, by Players

    • 3.1 Global Bio Similars/Subsequent Entry Biologic Revenue and Share by Players (2014-2019)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 Bio Similars/Subsequent Entry Biologic Players Market Share
      • 3.2.2 Top 10 Bio Similars/Subsequent Entry Biologic Players Market Share
    • 3.3 Market Competition Trend

    4 Global Bio Similars/Subsequent Entry Biologic Market Size by Regions

    • 4.1 Global Bio Similars/Subsequent Entry Biologic Revenue and Market Share by Regions
    • 4.2 North America Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 4.3 Europe Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 4.5 South America Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)

    5 North America Bio Similars/Subsequent Entry Biologic Revenue by Countries

    • 5.1 North America Bio Similars/Subsequent Entry Biologic Revenue by Countries (2014-2019)
    • 5.2 USA Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 5.3 Canada Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 5.4 Mexico Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)

    6 Europe Bio Similars/Subsequent Entry Biologic Revenue by Countries

    • 6.1 Europe Bio Similars/Subsequent Entry Biologic Revenue by Countries (2014-2019)
    • 6.2 Germany Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 6.3 UK Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 6.4 France Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 6.5 Russia Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 6.6 Italy Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue by Countries

    • 7.1 Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue by Countries (2014-2019)
    • 7.2 China Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 7.3 Japan Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 7.4 Korea Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 7.5 India Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)

    8 South America Bio Similars/Subsequent Entry Biologic Revenue by Countries

    • 8.1 South America Bio Similars/Subsequent Entry Biologic Revenue by Countries (2014-2019)
    • 8.2 Brazil Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 8.3 Argentina Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 8.4 Colombia Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)

    9 Middle East and Africa Revenue Bio Similars/Subsequent Entry Biologic by Countries

    • 9.1 Middle East and Africa Bio Similars/Subsequent Entry Biologic Revenue by Countries (2014-2019)
    • 9.2 Saudi Arabia Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 9.3 UAE Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 9.4 Egypt Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 9.5 Nigeria Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)
    • 9.6 South Africa Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2014-2019)

    10 Global Bio Similars/Subsequent Entry Biologic Market Segment by Type

    • 10.1 Global Bio Similars/Subsequent Entry Biologic Revenue and Market Share by Type (2014-2019)
    • 10.2 Global Bio Similars/Subsequent Entry Biologic Market Forecast by Type (2019-2024)
    • 10.3 Monoclonal Antibodies Revenue Growth Rate (2014-2024)
    • 10.4 Interferon Revenue Growth Rate (2014-2024)
    • 10.5 Erythropoietin Revenue Growth Rate (2014-2024)
    • 10.6 Insulin Revenue Growth Rate (2014-2024)
    • 10.7 Vaccines Revenue Growth Rate (2014-2024)
    • 10.8 Other Revenue Growth Rate (2014-2024)

    11 Global Bio Similars/Subsequent Entry Biologic Market Segment by Application

    • 11.1 Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Application (2014-2019)
    • 11.2 Bio Similars/Subsequent Entry Biologic Market Forecast by Application (2019-2024)
    • 11.3 Tumor Revenue Growth (2014-2019)
    • 11.4 Diabetes Revenue Growth (2014-2019)
    • 11.5 Cardiovascular Revenue Growth (2014-2019)
    • 11.6 Hemophilia Revenue Growth (2014-2019)
    • 11.7 Other Revenue Growth (2014-2019)

    12 Global Bio Similars/Subsequent Entry Biologic Market Size Forecast (2019-2024)

    • 12.1 Global Bio Similars/Subsequent Entry Biologic Market Size Forecast (2019-2024)
    • 12.2 Global Bio Similars/Subsequent Entry Biologic Market Forecast by Regions (2019-2024)
    • 12.3 North America Bio Similars/Subsequent Entry Biologic Revenue Market Forecast (2019-2024)
    • 12.4 Europe Bio Similars/Subsequent Entry Biologic Revenue Market Forecast (2019-2024)
    • 12.5 Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue Market Forecast (2019-2024)
    • 12.6 South America Bio Similars/Subsequent Entry Biologic Revenue Market Forecast (2019-2024)
    • 12.7 Middle East and Africa Bio Similars/Subsequent Entry Biologic Revenue Market Forecast (2019-2024)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Scope of the Report:
      The global Bio Similars/Subsequent Entry Biologic market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Bio Similars/Subsequent Entry Biologic.
      Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
      This report studies the Bio Similars/Subsequent Entry Biologic market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Bio Similars/Subsequent Entry Biologic market by product type and applications/end industries.

      Market Segment by Companies, this report covers
      Sun Pharma
      Synthon Pharmaceuticals
      Teva Pharmaceutical Industries
      LG Life Sciences
      Celltrion Biocon
      Hospira
      Merck
      Biogen idec
      Genentech (Roche)
      Pfizer
      Celltrion
      Biocon
      Amgen
      Samsung Biologics
      Mylan
      Dr. Reddy's Laboratories
      Stada Arzneimittel AG
      AbbVie
      Sanofi-Aventis
      Johnson & Johnson
      Novo Nordisk
      Eli Lilly
      Novartis
      3sbio
      Biotech
      Gelgen
      Innovent
      Dong Bao
      Ganlee

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Monoclonal Antibodies
      Interferon
      Erythropoietin
      Insulin
      Vaccines
      Other

      Market Segment by Applications, can be divided into
      Tumor
      Diabetes
      Cardiovascular
      Hemophilia
      Other

      Buy now